Common diabetes drug appears to lower breast cancer risk

Share this article:

Metformin, usually prescribed to help control blood glucose levels in persons with type 2 diabetes, may play a role in the prevention or management of breast cancer: The widely used oral drug has been linked with lower incidence of invasive breast cancer among participants in the Women's Health Initiative (WHI) clinical trials.

Rowan T. Chlebowski, MD, PhD, of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Los Angeles, California, and colleagues explained in Journal of Clinical Oncology that although emerging evidence suggests metformin may reduce breast cancer incidence, reports are mixed and few provide information on tumor characteristics. To assess the associations among diabetes, metformin use, and breast cancer, the researchers studied WHI study participants.

Of the 68,019 postmenopausal women followed, 3,401 had diabetes at study entry. Over a mean of 11.8 years, 3,273 invasive breast cancers were diagnosed. Women with diabetes using medications other than metformin had a slightly higher incidence of breast cancer compared to women without diabetes, but women with diabetes who were metformin users were less likely to have breast cancer. The association was seen for cancers positive for both estrogen receptor (ER-positive) and progesterone receptor (PR-positive), and for those that were negative for human epidermal growth factor receptor 2 (HER2-negative).

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.